{"id":204543,"name":"AIM IMMUNOTECH INC.","slug":"aim-immunotech-inc","state":"FL","country":"United States of America","description":"Biopharmaceutical company","totalSpending":600000,"filings":26,"yearlySpending":[{"year":2020,"income":90000},{"year":2021,"income":190000},{"year":2022,"income":120000},{"year":2023,"income":80000},{"year":2024,"income":80000},{"year":2025,"income":40000}],"issues":[{"code":"PHA","display":"Pharmacy"},{"code":"HCR","display":"Health Issues"}],"firms":["BUCHANAN INGERSOLL & ROONEY PC"],"lobbyists":["JAMES WILTRAUT","MICHAEL STRAZZELLA","KYLE DARBY","EDWARD HILD","ALICE NETTLES","SOPHIA ESTUPINAN"],"govEntities":["Defense, Dept of (DOD)","Food & Drug Administration (FDA)","HOUSE OF REPRESENTATIVES","Navy, Dept of","SENATE","Natl Institutes of Health (NIH)"],"sampleDescriptions":["Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics.","Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics.","Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics.","Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics.","Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics."]}